United Super Pty Ltd Boosts Gilead Sciences Stake by 132%

The Construction & Building Unions Superannuation Fund now holds $2.81 million in Gilead shares.

Published on Mar. 8, 2026

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 132.1% during the third quarter, according to the company's most recent disclosure with the Securities and Exchange Commission. The fund now owns 25,300 shares of the biopharmaceutical company's stock worth $2,808,000.

Why it matters

This investment by a major Australian pension fund highlights the continued institutional interest in Gilead Sciences, a leading biopharmaceutical company known for its antiviral therapies for HIV and viral hepatitis. The significant increase in the fund's Gilead stake suggests confidence in the company's growth prospects.

The details

United Super Pty Ltd added 14,400 shares of Gilead Sciences to its portfolio during the third quarter, bringing its total holdings to 25,300 shares. This represents a 132.1% increase in the fund's position. Gilead Sciences is a prominent biopharmaceutical company focused on developing and commercializing medicines in areas of high unmet medical need, including antiviral therapies, oncology, cell therapy, and inflammatory diseases.

  • United Super Pty Ltd disclosed the increased stake in a filing with the Securities and Exchange Commission on March 8, 2026.

The players

United Super Pty Ltd

An Australian pension fund that serves the construction and building unions superannuation industry.

Gilead Sciences, Inc.

A biopharmaceutical company focused on developing and commercializing medicines in areas of high unmet medical need, including antiviral therapies, oncology, cell therapy, and inflammatory diseases.

Got photos? Submit your photos here. ›

The takeaway

This investment by a major Australian pension fund highlights the continued institutional interest in Gilead Sciences, a leading biopharmaceutical company known for its antiviral therapies. The significant increase in the fund's Gilead stake suggests confidence in the company's growth prospects and its ability to develop innovative treatments for complex medical conditions.